On Nov. 5, 2020, Regeneron announced an update from the independent data monitoring committee (DMC) for the UK-based RECOVERY trial evaluating REGN-COV2 in hospitalized patients with COVID-19.

The DMC advised that, in the light of these data and the available external information, they saw no cogent reason to modify the protocol or intake to the study and recommended continuing recruitment of eligible patients to all study arms.